Agilent Technologies (A) Q3 2025 10-Q Quarterly Report

Filed: Aug 29, 2025Period ending Jul 31, 2025
Health Care
Laboratory Analytical InstrumentsSEC EDGAR

Agilent Technologies (A) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Aug 29, 2025 for the fiscal period ending Jul 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

Agilent Technologies Q3 2025 10-Q Analysis

Risk Factors

  • New risk: Continuing US federal agencies funding under resolution expiring Sept 30, 2025 may impact sales to federally funded customers
  • Material update: Increased risks from geopolitical conflicts (Ukraine/Russia, Middle East) and trade uncertainties affecting international operations
+3 more insights

Agilent Technologies Q3 2025 Quarterly Financials
XBRL

Revenue

$1.7B

+10.1% YoY +4.2% QoQ

Net Income

$336M

+19.1% YoY +56.3% QoQ

Operating Margin

20.7%

-39bp YoY +273bp QoQ

Net Margin

19.3%

+146bp YoY +644bp QoQ

EPS (Diluted)

$1.19

+22.7% YoY +58.7% QoQ

Operating Cash Flow

$362M

-19.9% YoY +63.8% QoQ

Source: XBRL data from Agilent Technologies Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Agilent Technologies Quarterly Reports

Get deeper insights on Agilent Technologies

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.